Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III study of gemcitabine versus TS-1 [S-1] versus gemcitabine plus TS-1 in unresectable advanced pancreatic cancer (with local progression or metastasis).

Next Previous
X
Search
Trial Profile

Randomized phase III study of gemcitabine versus TS-1 [S-1] versus gemcitabine plus TS-1 in unresectable advanced pancreatic cancer (with local progression or metastasis).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GEST
  • Sponsors Taiho Pharmaceutical; TTY Biopharm

    • Most Recent Events

    • 29 Dec 2015 Results (subgroup analysis) published in the European Journal of Cancer (n = 261).
    • 18 Jan 2014 Pooled results for prognostic factors from GEST, GEMSAP, and JACCRO PC-01 presented at the 2014 Gastrointestinal Cancers Symposium.
    • 03 Apr 2013 Results have been published in the online version of the Journal of Clinical Oncology according to a Taiho Pharmaceutical media release. Results were also summarised in the media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top